News >

Assessing Risk Stratification Across Pivotal Prostate Cancer Trials

Caroline Seymour
Published: Tuesday, Jan 08, 2019

Daniel Vaena, MD

Daniel Vaena, MD

By risk stratifying patients with prostate cancer, the growing armamentarium of available therapies can successfully be navigated, explained Daniel Vaena, MD, a medical oncologist and hematologist at West Cancer Center.

State of the Science Summit™ on Genitourinary Cancers, Vaena discussed the treatment of patients with metastatic castration-naïve disease and nonmetastatic CRPC, underscoring the importance of risk stratification in both settings.

OncLive: What should be emphasized about the treatment of these patients with prostate cancer?

Vaena: There are many new treatments available today for patients who have newly diagnosed metastatic castration-naïve disease who are going to receive hormonal therapy plus additional systemic therapies. In the trials done to date, all of those patients have been risk stratified [based on their burden of disease]. There’s no uniform rule for how these patients should be treated, so it's important to know how much burden of disease they have in order to understand what the additional benefit is going to be from those treatments.

The same thing applies to patients who have nonmetastatic disease. These trials have also stratified, or selected patients based on more aggressive features, such as prostate specific antigen (PSA) doubling times. The current recommendations and approvals don't apply to every patient with nonmetastatic disease, so it's important to understand the therapeutic space and the risk stratification of the patients you're treating.

What are the available therapies for these patients and what are their selection criteria?

There are 3 different therapeutic spaces that we talk about. The first setting is castration naïve, in which the patient has never had hormonal therapy but has a biochemical relapse. For those patients, the standard of care would be to either observe the PSA and hold off on hormonal therapy, or start hormonal therapy. There are not a lot of new data on adding new treatments on top of hormonal therapy for these patients with nonmetastatic castration-naïve disease.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication